Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients

AIDS

Volumn 19, Issue 15, 2005, Pages 1575-1585

  Legrand, Fatema A ^a,e   Abadi, Jacob ^b   Jordan, Kimberly A ^a   Davenport, Miles P ^c   Deeks, Steve G ^d   Fennelly, Glenn J ^b   Wiznia, Andrew A ^b   Nixon, Douglas F ^a   Rosenberg, Michael G ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NONE   (United States)

Author keywords

Antiretroviral therapy; CD8; HIV; Partial treatment interruption; Pediatric; Protease inhibitor; T cells

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LONGITUDINAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

EID: 27144433671     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000186816.99993.8e     Document Type: Article

References (39)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR 3rd, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345: 1522-1528.
3. Gibb DM, Duong T, Tookey PA, Sharland M, Tudor-Williams G, Novelli V, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003; 327:1019.
4. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280:1497-1503.
5. de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000; 284:190-197.
6. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999; 340:1614-1622.
7. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300.
8. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727-728.
9. Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, O'Shaughnessy MV, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15:231-239.
10. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
11. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with anti-retroviral combination therapy. J Infect Dis 2002; 186:23-31.
12. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23:35-43.
13. Thiebaut R, Daucourt V, Mercie P, Ekouevi DK, Malvy D, Morlat P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis 2000; 31:1482-1487.
14. Stephenson J. AIDS researchers target poor adherence. JAMA 1999; 281:1069.
15. Brackis-Cott E, Mellins CA, Abrams E, Reval T, Dolezal C. Pediatric HIV medication adherence: the views of medical providers from two primary care programs. J Pediatr Health Care 2003; 17:252-260.
16. Ruiz L, Ribera E, Bonjoch A, Romeu J, Martinez-Picado J, Paredes R, et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. J Infect Dis 2003; 188:977-985.
17. Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837-846.
18. Carcelain G, Tubiana R, Samri A, Calvez V, Delaugerre C, Agut H, et al. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol 2001; 75:234-241.
19. Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A, et al. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis 2002; 185:315-323.
20. Deeks SG, Martin JN, Hoh R, Wrin T, Petropoulos C, Grant RM. Continued Reverse Transcriptase Inhibitor Therapy is Sufficient to Maintain Short-Term Partial Suppression of Multi-drug Resistant Viremia. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003.
21. Andre P, Groettrup M, Klenerman P, de Giuli R, Booth BL Jr, Cerundolo V, et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 1998; 95:13120-13124.
22. Chavan S, Kodoth S, Pahwa R, Pahwa S. The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. Blood 2001; 98:383-389.
23. Burton CT, Hardy CA, Sullivan AK, Nelson MR, Cazzard B, Cotch FM, et al. Impact of NNRTI compared to PI-based highly active antiretroviral therapy on CCR5 receptor expression, beta-chemokines and IL-16 secretion in HIV-1 infection. Clin Exp Immunol 2002; 130:286-292.
24. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003; 362:2002-2011.
25. Lichterfeld M, Yu XC, Waring MT, Mui SK, Johnston MN, Cohen D, et al. HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha. Blood 2004; 104:487-494.
26. Kelleher AD, Booth BL Jr, Sewell AK, Oxenius A, Cerundolo V, McMichael AJ, et al. Effects of retroviral protease inhibitors on proteasome function and processing of HIV-derived MHC class I-restricted cytotoxic T lymphocyte epitopes. AIDS Res Hum Retroviruses 2001; 17:1063-1066.
27. Lopez M, Benito JM, Lozano S, Barreiro P, Martinez P, Gonzalez-Lahoz J, et al. Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea. AIDS 2004; 18:1251-1261.
28. Sullivan AK, Burton CT, Nelson MR, et al. Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Scand J Immunol 2003; 57:600-607.
29. Hardy GA, Imami N, Sullivan AK, Pires A, Burton CT, Nelson MR, et al. Reconstitution of CD4+ T cell responses in HIV-1 infected individuals initiating highly active antiretroviral therapy (HAART) is associated with renewed interleukin-2 production and responsiveness. Clin Exp Immunol 2003; 134:98-106.
30. Ikezoe T, Daar ES, Hisatake J, Taguchi H, Koeffler HP. HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood 2000; 96:3553-3559.
31. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001;7:1327-1331.
32. Wang MW, Wei S, Faccio R, Takeshita S, Tebas P, Powderly WG, et al. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest 2004; 114:206-213.
33. Gaedicke S, Firat-Geier E, Constantiniu O, Lucchiari-Hartz M, Freudenberg M, Galanos C, et al. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 2002; 62:6901-6908.
34. Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics. Ann Intern Med 2001; 134:978-996.
35. Campo RE, Rosa I, Lichtenberger PN, Suarez G, Rivera FA, Jayaweera DT, et al. Effect of class-specific therapy interruption on persistence of HIV type 1 antiretroviral resistance. AIDS Res Hum Retroviruses 2003; 19:653-656.
36. Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, Kazmi S, et al. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity. J Virol 2003; 77:6041-6049.
37. Deeks SG, Martin JN, Sinclair E, Harris J, Neilands TB, Maecker HT, et al. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis 2004; 189:312-321.
38. Whelan KT, Lin CL, Cella M, McMichael AJ, Austyn JM, Rowland-Jones SL. The HIV protease inhibitor indinavir reduces immature dendritic cell transendothelial migration. Eur J Immunol 2003; 33:2520-2530.
39. Yu Q, Gu JX, Kovacs C, Freedman J, Thomas EK, Ostrowski MA. Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. J Immunol 2003; 170:1797-1805.